{"id":"https://openalex.org/W2069838435","doi":"https://doi.org/10.1097/iae.0b013e3180323de7","title":"TRIPLE THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION: Verteporfin PDT, Bevacizumab, and Dexamethasone","display_name":"TRIPLE THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION: Verteporfin PDT, Bevacizumab, and Dexamethasone","alternate_titles":[],"publication_year":2007,"publication_date":"2007-02-01","ids":{"openalex":"https://openalex.org/W2069838435","doi":"https://doi.org/10.1097/iae.0b013e3180323de7","mag":"2069838435","pmid":"https://pubmed.ncbi.nlm.nih.gov/17290193"},"language":"en","primary_location":{"id":"doi:10.1097/iae.0b013e3180323de7","doi":"https://doi.org/10.1097/iae.0b013e3180323de7","is_oa":false,"landing_page_url":"https://doi.org/10.1097/iae.0b013e3180323de7","pdf_url":null,"source":{"id":"https://openalex.org/S19572933","display_name":"Retina","issn_l":"0275-004X","issn":["0275-004X","1539-2864"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Retina","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2069838435"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5084748737","display_name":"Albert J. Augustin","orcid":"https://orcid.org/0000-0003-1591-0536","observed_orcids":["https://orcid.org/0000-0003-1591-0536"]},"institutions":[{"id":"https://openalex.org/I4210090715","display_name":"St\u00e4dtisches Klinikum Karlsruhe","ror":"https://ror.org/00agtat91","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210090715"]},{"id":"https://openalex.org/I4405281623","display_name":"Macula Society","ror":"https://ror.org/04n2g0t92","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4405281623"]}],"countries":["DE","US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"ALBERT J. AUGUSTIN","raw_affiliation_strings":["Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany. 106020.560@compuserve.com","ARVO, Fort Lauderdale, May 2006","Macula Society, San Diego, February 2006","Neither author has a proprietary interest in verteporfin, bevacizumab, or dexamethasone","Preliminary results of this case series were presented at Masters Meeting, Puerto Rico, February 2006","the Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany","the RPS, Nassau, June 2006","the Retina Subspecialty Day, Las Vegas, November 2006"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany. 106020.560@compuserve.com","institution_ids":["https://openalex.org/I4210090715"]},{"raw_affiliation_string":"ARVO, Fort Lauderdale, May 2006","institution_ids":[]},{"raw_affiliation_string":"Macula Society, San Diego, February 2006","institution_ids":["https://openalex.org/I4405281623"]},{"raw_affiliation_string":"Neither author has a proprietary interest in verteporfin, bevacizumab, or dexamethasone","institution_ids":[]},{"raw_affiliation_string":"Preliminary results of this case series were presented at Masters Meeting, Puerto Rico, February 2006","institution_ids":[]},{"raw_affiliation_string":"the Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany","institution_ids":["https://openalex.org/I4210090715"]},{"raw_affiliation_string":"the RPS, Nassau, June 2006","institution_ids":[]},{"raw_affiliation_string":"the Retina Subspecialty Day, Las Vegas, November 2006","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"STEPHAN PULS","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210090715","display_name":"St\u00e4dtisches Klinikum Karlsruhe","ror":"https://ror.org/00agtat91","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210090715"]},{"id":"https://openalex.org/I4210139524","display_name":"Association for Research in Vision and Ophthalmology","ror":"https://ror.org/033523d69","country_code":"US","type":"other","lineage":["https://openalex.org/I4210139524"]},{"id":"https://openalex.org/I4405281623","display_name":"Macula Society","ror":"https://ror.org/04n2g0t92","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4405281623"]}],"countries":["DE","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"STEPHAN PULS","raw_affiliation_strings":["Neither author has a proprietary interest in verteporfin, bevacizumab, or dexamethasone","Preliminary results of this case series were presented at Masters Meeting, Puerto Rico, February 2006; Macula Society, San Diego, February 2006; ARVO, Fort Lauderdale, May 2006; the RPS, Nassau, June 2006; and the Retina Subspecialty Day, Las Vegas, November 2006","the Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany","ARVO, Fort Lauderdale, May 2006","Macula Society, San Diego, February 2006","Preliminary results of this case series were presented at Masters Meeting, Puerto Rico, February 2006","the RPS, Nassau, June 2006","the Retina Subspecialty Day, Las Vegas, November 2006"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neither author has a proprietary interest in verteporfin, bevacizumab, or dexamethasone","institution_ids":[]},{"raw_affiliation_string":"Preliminary results of this case series were presented at Masters Meeting, Puerto Rico, February 2006; Macula Society, San Diego, February 2006; ARVO, Fort Lauderdale, May 2006; the RPS, Nassau, June 2006; and the Retina Subspecialty Day, Las Vegas, November 2006","institution_ids":["https://openalex.org/I4210139524","https://openalex.org/I4405281623"]},{"raw_affiliation_string":"the Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany","institution_ids":["https://openalex.org/I4210090715"]},{"raw_affiliation_string":"ARVO, Fort Lauderdale, May 2006","institution_ids":[]},{"raw_affiliation_string":"Macula Society, San Diego, February 2006","institution_ids":["https://openalex.org/I4405281623"]},{"raw_affiliation_string":"Preliminary results of this case series were presented at Masters Meeting, Puerto Rico, February 2006","institution_ids":[]},{"raw_affiliation_string":"the RPS, Nassau, June 2006","institution_ids":[]},{"raw_affiliation_string":"the Retina Subspecialty Day, Las Vegas, November 2006","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5045267317","display_name":"I. Offermann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210090715","display_name":"St\u00e4dtisches Klinikum Karlsruhe","ror":"https://ror.org/00agtat91","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210090715"]},{"id":"https://openalex.org/I4210139524","display_name":"Association for Research in Vision and Ophthalmology","ror":"https://ror.org/033523d69","country_code":"US","type":"other","lineage":["https://openalex.org/I4210139524"]},{"id":"https://openalex.org/I4405281623","display_name":"Macula Society","ror":"https://ror.org/04n2g0t92","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4405281623"]}],"countries":["DE","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"INDRE OFFERMANN","raw_affiliation_strings":["Neither author has a proprietary interest in verteporfin, bevacizumab, or dexamethasone","Preliminary results of this case series were presented at Masters Meeting, Puerto Rico, February 2006; Macula Society, San Diego, February 2006; ARVO, Fort Lauderdale, May 2006; the RPS, Nassau, June 2006; and the Retina Subspecialty Day, Las Vegas, November 2006","the Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany","ARVO, Fort Lauderdale, May 2006","Macula Society, San Diego, February 2006","Preliminary results of this case series were presented at Masters Meeting, Puerto Rico, February 2006","the RPS, Nassau, June 2006","the Retina Subspecialty Day, Las Vegas, November 2006"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neither author has a proprietary interest in verteporfin, bevacizumab, or dexamethasone","institution_ids":[]},{"raw_affiliation_string":"Preliminary results of this case series were presented at Masters Meeting, Puerto Rico, February 2006; Macula Society, San Diego, February 2006; ARVO, Fort Lauderdale, May 2006; the RPS, Nassau, June 2006; and the Retina Subspecialty Day, Las Vegas, November 2006","institution_ids":["https://openalex.org/I4210139524","https://openalex.org/I4405281623"]},{"raw_affiliation_string":"the Department of Ophthalmology, Klinikum Karlsruhe, Karlsruhe, Germany","institution_ids":["https://openalex.org/I4210090715"]},{"raw_affiliation_string":"ARVO, Fort Lauderdale, May 2006","institution_ids":[]},{"raw_affiliation_string":"Macula Society, San Diego, February 2006","institution_ids":["https://openalex.org/I4405281623"]},{"raw_affiliation_string":"Preliminary results of this case series were presented at Masters Meeting, Puerto Rico, February 2006","institution_ids":[]},{"raw_affiliation_string":"the RPS, Nassau, June 2006","institution_ids":[]},{"raw_affiliation_string":"the Retina Subspecialty Day, Las Vegas, November 2006","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5084748737"],"corresponding_institution_ids":["https://openalex.org/I4210090715","https://openalex.org/I4405281623"],"apc_list":null,"apc_paid":null,"fwci":29.1147,"has_fulltext":false,"cited_by_count":204,"citation_normalized_percentile":{"value":0.99870758,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":91,"max":100},"biblio":{"volume":"27","issue":"2","first_page":"133","last_page":"140"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11377","display_name":"Retinal and Macular Surgery","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11194","display_name":"Ocular Diseases and Beh\u00e7et\u2019s Syndrome","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/choroidal-neovascularization","display_name":"choroidal neovascularization","score":0.9679999947547913},{"id":"https://openalex.org/keywords/age-related-macular-degeneration","display_name":"age-related macular degeneration","score":1.0},{"id":"https://openalex.org/keywords/triple-therapy","display_name":"triple therapy","score":0.8840000033378601},{"id":"https://openalex.org/keywords/verteporfin-photodynamic-therapy","display_name":"verteporfin photodynamic therapy","score":0.9760000109672546},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.9120000004768372},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.996999979019165},{"id":"https://openalex.org/keywords/intravitreal-injection","display_name":"intravitreal injection","score":0.9639999866485596},{"id":"https://openalex.org/keywords/visual-acuity","display_name":"visual acuity","score":0.7229999899864197},{"id":"https://openalex.org/keywords/retinal-thickness","display_name":"retinal thickness","score":0.9739999771118164},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.7860000133514404},{"id":"https://openalex.org/keywords/cnv-recurrence","display_name":"CNV recurrence","score":0.7329999804496765}],"concepts":[{"id":"https://openalex.org/C2781148688","wikidata":"https://www.wikidata.org/wiki/Q782318","display_name":"Verteporfin","level":4,"score":0.9699866771697998},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9252637624740601},{"id":"https://openalex.org/C2781359195","wikidata":"https://www.wikidata.org/wiki/Q5105209","display_name":"Choroidal neovascularization","level":3,"score":0.8705307245254517},{"id":"https://openalex.org/C2776403814","wikidata":"https://www.wikidata.org/wiki/Q27429789","display_name":"Macular degeneration","level":2,"score":0.7433454394340515},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.694678783416748},{"id":"https://openalex.org/C2778257484","wikidata":"https://www.wikidata.org/wiki/Q555066","display_name":"Visual acuity","level":2,"score":0.6745439171791077},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.6515477895736694},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.6238169074058533},{"id":"https://openalex.org/C2781323092","wikidata":"https://www.wikidata.org/wiki/Q1428072","display_name":"Photodynamic therapy","level":2,"score":0.6115174293518066},{"id":"https://openalex.org/C2780248432","wikidata":"https://www.wikidata.org/wiki/Q1434206","display_name":"Fluorescein angiography","level":3,"score":0.5637047290802002},{"id":"https://openalex.org/C2781092963","wikidata":"https://www.wikidata.org/wiki/Q650050","display_name":"Intraocular pressure","level":2,"score":0.4148171544075012},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.411589115858078},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.37036705017089844},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.16814875602722168},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.12485146522521973},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077362","descriptor_name":"Verteporfin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005451","descriptor_name":"Fluorescein Angiography","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005938","descriptor_name":"Glucocorticoids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007267","descriptor_name":"Injections","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007429","descriptor_name":"Intraocular Pressure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008268","descriptor_name":"Macular Degeneration","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D008268","descriptor_name":"Macular Degeneration","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010778","descriptor_name":"Photochemotherapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011166","descriptor_name":"Porphyrins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014822","descriptor_name":"Vitreous Body","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017319","descriptor_name":"Photosensitizing Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D020256","descriptor_name":"Choroidal Neovascularization","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D020256","descriptor_name":"Choroidal Neovascularization","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D041623","descriptor_name":"Tomography, Optical Coherence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1097/iae.0b013e3180323de7","doi":"https://doi.org/10.1097/iae.0b013e3180323de7","is_oa":false,"landing_page_url":"https://doi.org/10.1097/iae.0b013e3180323de7","pdf_url":null,"source":{"id":"https://openalex.org/S19572933","display_name":"Retina","issn_l":"0275-004X","issn":["0275-004X","1539-2864"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Retina","raw_type":"journal-article"},{"id":"pmid:17290193","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17290193","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Retina (Philadelphia, Pa.)","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.463.4288","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.463.4288","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://www.augenaerzte-baden-baden.de/cms/docs/doc36416.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":50,"referenced_works":["https://openalex.org/W5086926","https://openalex.org/W105145916","https://openalex.org/W945208301","https://openalex.org/W1522623672","https://openalex.org/W1522773084","https://openalex.org/W1546928690","https://openalex.org/W1588907756","https://openalex.org/W1601975653","https://openalex.org/W1802218256","https://openalex.org/W1968078122","https://openalex.org/W1968609549","https://openalex.org/W1972040236","https://openalex.org/W1978199957","https://openalex.org/W1985156621","https://openalex.org/W1985357192","https://openalex.org/W1995708259","https://openalex.org/W2000186122","https://openalex.org/W2001150235","https://openalex.org/W2001615886","https://openalex.org/W2001655253","https://openalex.org/W2008781112","https://openalex.org/W2008965058","https://openalex.org/W2013295026","https://openalex.org/W2025610712","https://openalex.org/W2027693928","https://openalex.org/W2028560967","https://openalex.org/W2029126623","https://openalex.org/W2034554496","https://openalex.org/W2045317893","https://openalex.org/W2046606959","https://openalex.org/W2054820629","https://openalex.org/W2056392188","https://openalex.org/W2057900897","https://openalex.org/W2063810817","https://openalex.org/W2064923609","https://openalex.org/W2077129920","https://openalex.org/W2092816889","https://openalex.org/W2101095025","https://openalex.org/W2106384168","https://openalex.org/W2113050427","https://openalex.org/W2117386992","https://openalex.org/W2123959516","https://openalex.org/W2143419021","https://openalex.org/W2144839999","https://openalex.org/W2147641426","https://openalex.org/W2153824094","https://openalex.org/W2291374210","https://openalex.org/W3145351529","https://openalex.org/W6696764971","https://openalex.org/W6986394994"],"related_works":["https://openalex.org/W1987005874","https://openalex.org/W1996044788","https://openalex.org/W2104232975","https://openalex.org/W2143419021","https://openalex.org/W2164873119","https://openalex.org/W2332855465","https://openalex.org/W1979874741","https://openalex.org/W2013275404","https://openalex.org/W2142979206","https://openalex.org/W1588907756"],"abstract_inverted_index":{"In":[0,188,212],"Brief":[1],"Purpose:":[2],"To":[3],"evaluate":[4],"the":[5,214,262],"efficacy":[6],"and":[7,18,67,84,89,92,201,233,244],"safety":[8,219],"of":[9,56,146,210,251,257,261,283],"triple":[10,117,125,133,196,278],"therapy":[11,15,118,134,197,215,238,279],"with":[12,44,191,225,239,264,277],"verteporfin":[13,240],"photodynamic":[14,241],"(PDT),":[16],"dexamethasone,":[17],"bevacizumab":[19,68],"in":[20,137,160,171,199,247,259],"choroidal":[21,265],"neovascularization":[22,266],"(CNV)":[23],"secondary":[24],"to":[25,128,194,268,281],"age-related":[26,269],"macular":[27,270],"degeneration":[28],"(AMD).":[29],"Methods:":[30],"This":[31],"prospective,":[32],"noncomparative,":[33],"interventional":[34],"case":[35],"series":[36],"included":[37],"104":[38,113],"patients.":[39,236],"Verteporfin":[40],"PDT":[41],"was":[42,99,135,152,163,174],"administered":[43,230],"a":[45,123,217,248],"reduced":[46],"light":[47,53],"dose":[48],"(42":[49],"J/cm2,":[50],"accomplished":[51],"by":[52,141],"delivery":[54],"time":[55],"70":[57],"seconds).":[58],"Approximately":[59],"16":[60],"hours":[61],"after":[62,206,254],"PDT,":[63],"dexamethasone":[64,245],"(800":[65],"\u03bcg)":[66],"(1.5":[69],"mg)":[70],"were":[71],"injected":[72],"intravitreally.":[73],"Patients":[74],"attended":[75],"follow-up":[76,150],"visits":[77],"every":[78,101],"6":[79],"weeks,":[80],"undergoing":[81],"visual":[82,161,203],"acuity":[83,162,204],"intraocular":[85],"pressure":[86],"measurement,":[87],"slit-lamp":[88],"ophthalmoscopic":[90],"examination,":[91],"optical":[93],"coherence":[94],"tomography":[95],"(OCT).":[96],"Fluorescein":[97],"angiography":[98],"performed":[100],"3":[102],"months":[103],"or":[104],"earlier":[105],"if":[106],"OCT":[107],"showed":[108],"significant":[109,200,249],"edema.":[110],"Results:":[111],"All":[112],"patients":[114,121,139,190,263,274],"received":[115,122],"one":[116,208,255],"cycle":[119,209,256],"(5":[120],"second":[124],"treatment":[126,258],"due":[127,193,267,280],"remaining":[129],"CNV":[130,192,284],"activity).":[131],"The":[132,148],"complemented":[136],"18":[138],"(17.3%)":[140],"an":[142],"additional":[143],"intravitreal":[144],"injection":[145],"bevacizumab.":[147],"mean":[149,252],"period":[151],"40":[153],"weeks":[154],"(range,":[155],"22\u201360":[156],"weeks).":[157],"Mean":[158,169],"increase":[159,250],"1.8":[164],"lines":[165],"(P":[166,177],"<":[167,178],"0.01).":[168,179],"decrease":[170],"retinal":[172],"thickness":[173],"182":[175],"\u03bcm":[176],"No":[180],"serious":[181],"adverse":[182],"events":[183],"have":[184],"been":[185],"observed.":[186],"Conclusion:":[187],"most":[189,260],"AMD,":[195],"results":[198,246],"sustained":[202],"improvement":[205],"only":[207],"treatment.":[211],"addition,":[213],"offers":[216],"good":[218],"profile,":[220],"potentially":[221],"lower":[222],"cost":[223],"compared":[224],"therapies":[226],"that":[227],"must":[228],"be":[229],"more":[231],"frequently,":[232],"convenience":[234],"for":[235],"Triple":[237],"therapy,":[242],"bevacizumab,":[243],"VA":[253],"degeneration.":[271],"Only":[272],"5":[273],"needed":[275],"retreatment":[276],"recurrency":[282],"activity.":[285]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2069838435","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":14},{"year":2014,"cited_by_count":13},{"year":2013,"cited_by_count":10},{"year":2012,"cited_by_count":10}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
